Compare Inovio Pharmaceuticals Inc (INO) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Msci Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Msci Inc trades at $571.28 (market cap $45.51B). The key difference: Msci Inc is far larger — about 509.8× Inovio Pharmaceuticals Inc's market cap, and Msci Inc pays a 1.31% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | MSCI | |
|---|---|---|
Market Cap | $89.27M | $45.51B |
Sector | Health | Financials |
52-Week High | $2.87 | $643.83 |
52-Week Low | $1.05 | $511.84 |
Enterprise Value | $60.28M | $51.67B |
Dividend Yield | — | 1.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
MSCI trades at $625.11, down 0.56% on the day, with a bullish technical outlook supported by moving averages and a recent strategic partnership with UBS to enhance its private markets platform. The company shows strong fundamentals with a 40.74% net income margin and consistent earnings beats, though valuation ratios like a P/E of 35.9 suggest a premium. Analyst consensus is strongly bullish with a $723.38 price target, and cash flow turned positive in 2025 after prior years of net outflows.
The outlook for MSCI is positive, driven by earnings growth, high profitability, and strategic expansions, but risks include elevated debt levels and sensitivity to financial market conditions. The stock offers a dividend yield supported by solid cash generation, though investors should weigh the high valuation against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
